Biotech & Medtech
Biotech & Medtech news today
34 stories from 4 sources in the last 48 hours, every one in English. Each links to its publisher.
-
BIO unveils plan for US to remain biotech’s ‘global leader’
BioPharma Dive
A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.
-
STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
STAT News
Ionis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug the biotech and Wall Street analysts believe is a potential blockbuster. The firm…
-
Startup Supporting Caregivers Raises $3.5M in Seed Funding
MedCity News
Avanlee Care’s seed round was led by BEA Venture Fund, with participation from existing investors, including Board Chair Esther Dyson, Chrysalis Ventures and FairBridge VC. The post Startup Supporting Caregivers Raises $3.5M in Seed…
-
Bayer wins FDA nod for a new kind of blood thinner
BioPharma Dive
Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
-
STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke
STAT News
The Food and Drug Administration on Monday approved Bayer’s drug to reduce recurrence of stroke, making available the first in a novel class of medications that hold the promise of preventing blood clots more safely. Many blood thinners…
-
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
MedCity News
In a panel discussion, executives from Noom, Omada, Virta and Twin Health discussed how they are going beyond the pill in their GLP-1 strategy and responded to a question about whether they will exist two-to-three years from now. The post…
-
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
MedCity News
Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies. The post Argenx Adds Oral…
-
STAT+: Trump administration removes WuXi AppTec from its Chinese military list
STAT News
After months of skirmishing, the Trump administration removed WuXi AppTec, a key contract developer and manufacturer for the pharmaceutical industry, from its list of “Chinese military companies” operating in the U.S. The Department of…
-
STAT+: Bill Ackman’s bold plan to transform brain research
STAT News
NEW YORK — If you’re blind, Bill Ackman wants to help you see again. That is the ambitious plan the billionaire is pursuing with the Ackman Oxman Institute, a new institution in New York City that will act as a hub for brain injury…
-
STAT+: Hospitals win the midterms, and Chopping Very Strategically
STAT News
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here . Are you looking to mix up your Spotify? Try Balu Brigada. The band is from New Zealand and has a ton of bops, like “ BedHead .” Comments, song…
-
Vir hepatitis D drug succeeds in first pivotal study
BioPharma Dive
A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.
-
STAT+: Heart association meeting’s readout is trending ‘neutral’
STAT News
CHICAGO — If one word could describe research presented at this year’s American Heart Association scientific sessions, it might be “neutral.” The meeting began with two blockbuster disappointments, hinted at in top-line results released…
-
Argenx to buy peptide platform in potentially billion-dollar deal
BioPharma Dive
For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.
-
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
STAT News
The Food and Drug Administration on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharma companies to inform patients and doctors of the risk. The condition, called non-arteritic…
-
Ramaswamy’s biotech baggage haunted his political run
BioPharma Dive
A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
-
Simulation-Guided Clinical Trials: Is EU Law Ready?
MedCity News
Simulations do not replace human judgment: they inform it, making transparent what would otherwise remain a “black box.” EU law does not require them today; but a proportionate embrace, in the right legislative vehicle, with clear…
-
STAT+: Gene therapy’s long-debated cancer risk materializes
STAT News
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The tumors possibly connected to pediatric gene therapies make me sad. Babies. The need-to-know this morning Vir…
-
STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
STAT News
Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn’t appear as effective as Lilly’s injectable drug Zepbound. In a one-year trial of patients who weren’t receiving PAP therapy, a form of…
-
STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
STAT News
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the usual routine of online meetings, phone calls, and deadlines has returned. You knew this would happen, yes?…
-
STAT+: A new rule to prevent the spread of bioweapons
STAT News
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Hello and happy Monday! We’ve got a lot in store for you today — a first look at Democrats’ big health plans, some gossip…
-
Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
MedCity News
Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology annual in Orlando this week. The biotech is part of a growing…
-
Making the ‘impossible’ executable in life sciences construction
BioPharma Dive
Why early technical expertise matters when complex life sciences projects challenge convention.
-
State incentives for commercial-stage life sciences companies
BioPharma Dive
Factor incentives into expansion plans early to improve site decisions, manage commitments and free capital for what comes next.
-
Translating Phase II success into Phase III readiness takes more than scale
BioPharma Dive
The move from Phase II to Phase III is often treated as a clinical milestone, when it is actually a development-wide transition.
-
STAT+: Democrats begin asking: How far can we go on health care?
STAT News
WASHINGTON — In the first days following their sweeping midterms victory, Democrats are asking themselves: How far can we go? That question has grown particularly interesting in health care — a policy area that many Democrats argue was…
-
AI chatbots aren’t therapists. But can they finally get men to open up?
STAT News
It was mid-morning when Matteo got the phone call. His wife and children were asleep in New York City, and he was at work in Trieste, Italy, a new city in a home country that felt foreign after decades abroad. He knew what his brother was…
-
Liver experts finally agree on what acute-on-chronic liver failure is
STAT News
Liver doctors from around the world have come to agree on a definition for a common and potentially fatal liver complication. Acute-on-chronic liver failure is what happens when someone with underlying liver disease has their condition…
-
Opinion: STAT+: CVS’ split doesn’t fix its fundamental problem
STAT News
CVS Health is one of the largest companies in the U.S. It serves the health care needs of hundreds of millions of Americans annually, has a hand in nearly every part of the drug supply chain, and has more than $400 billion in annual…
-
Two-Layer Evolutionary Scheduling for Machine Learning Jobs in Multi-Cluster Environments
arXiv cs.NE (Neural／Bio)
arXiv:2611.09093v1 Announce Type: new Abstract: The rapid growth of large-scale machine learning (ML) workloads has led to unprecedented demands on GPU cluster scheduling systems. However, existing heuristic schedulers struggle to handle…
-
OMCDE: Opposition-based Multi-Stage Matrix-Based Competitive Differential Evolution
arXiv cs.NE (Neural／Bio)
arXiv:2611.09167v1 Announce Type: new Abstract: Differential Evolution has proven to be an effective algorithm for continuous global optimization, but it's modern high-performing variants often introduce additional complexity and…
-
What’s Driving the Consumerization of Healthcare?
MedCity News
Patients increasingly expect convenient, consumer-focused healthcare experiences, panelists said at the recent MedCity INVEST Digital Health Conference. The post What’s Driving the Consumerization of Healthcare? appeared first on MedCity…
-
Survival after sudden cardiac arrest didn’t improve despite training bystanders, emergency responders
STAT News
CHICAGO — Sudden cardiac arrest statistics are chilling. In the United States, 350,000 people’s heartbeats, breathing, pulse, and blood circulation will all halt outside hospitals this year, seemingly out of the blue . These are not heart…
-
Missing the Point: Isolation Alone Will Not Build AI Safety
MedCity News
Treating AI agents like contract nurses and minimizing their access to critical patient information certainly reduces potential risk. But, it also minimizes key opportunities. The post Missing the Point: Isolation Alone Will Not Build AI…
-
STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
STAT News
The next time someone tells you that artificial intelligence , or any other new technology, is going to cure every disease , point them to the effort to fight heart attacks and strokes, which together are the largest killer in the…